NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Bicara Therapeutics Inc. (BCAX) Stock Analysis

Bicara Therapeutics Inc. (BCAX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

BCAX

$23.17

−$0.17 (−0.73%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare BCAX with… →

BCAX Key Statistics

As of Sep 4, 2026
Trading
Open
$23.09
Previous Close
$23.34
Day's Range
22.85–23.47
52-Week Range
10.30–30.99
Volume
296.90K
Valuation
Market Cap
$1.53B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.07
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$137.95M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
66.17M
1-Year Return
+92.12%
Dividend and dates
Earnings Date
November 10, 2026
Avg Volume
725.02K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

BCAX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+37.67%
2025−3.39%
2024 (partial year)−25.59%

As of September 4, 2026.

BCAX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$137.95M—
2024$0.00−$68.00M—
2023$0.00−$51.99M—
2022$0.00−$37.85M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$155.60M−$137.95M—
2024$0.00—−$82.39M−$68.00M—
2023$0.00—−$39.89M−$51.99M—
2022$0.00—−$37.66M−$37.85M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

BCAX Valuation vs Biotechnology Median

Median of 656 stocks
MetricBCAXBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 13 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Bicara Therapeutics Inc. (BCAX) is capitalised at $1.53B on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 103 employees.

BCAX last closed at $23.17 on September 4, 2026. That is −$0.17 (−0.73%) against the previous close. The 52-week range on file runs from $10.30 to $30.99. The latest close sits 125.06% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $137.95M. Profit margin runs at 0%. Trailing earnings per share are −3.07.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Daily returns over the trailing 2 years annualize to a volatility of 74.84%. Over the trailing twelve months the price has returned +92.12%. The stored price history starts on September 13, 2024, and the total return since then is −1.03%.

Growth & Income

No dividend is on file for BCAX.

2026 is still running; the price is +37.67% year to date. The record holds one complete calendar year, 2025, which returned −3.39%.

Peer Comparison

Bicara Therapeutics Inc. (BCAX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Bicara Therapeutics Inc. BCAX $1.53B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Bicara Therapeutics Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Bicara Therapeutics Inc.

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Visit website →